Alto Neuroscience (NYSE:ANRO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Alto Neuroscience (NYSE:ANRO) from a sell rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

Several other equities research analysts have also recently issued reports on ANRO. BTIG Research raised their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Wolfe Research assumed coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Robert W. Baird dropped their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Finally, Bank of America initiated coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target for the company. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.25.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $35.30 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The stock’s fifty day moving average is $29.03 and its two-hundred day moving average is $24.30. The firm has a market capitalization of $1.39 billion, a P/E ratio of -14.59 and a beta of 1.06. Alto Neuroscience has a fifty-two week low of $3.41 and a fifty-two week high of $37.48.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. On average, research analysts anticipate that Alto Neuroscience will post -2.68 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of ANRO. Northwestern Mutual Wealth Management Co. lifted its position in Alto Neuroscience by 14,567.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after buying an additional 211,222 shares during the last quarter. Perceptive Advisors LLC boosted its stake in Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after buying an additional 225,500 shares during the period. Jennison Associates LLC acquired a new stake in shares of Alto Neuroscience during the first quarter valued at about $8,687,000. AWM Investment Company Inc. acquired a new stake in shares of Alto Neuroscience during the second quarter valued at about $2,111,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Alto Neuroscience in the 1st quarter valued at approximately $538,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.